A phase II trial of ifosfamide, 5-fluorouracil, and leucovorin in recurrent uterine cervical cancer.
Thirty patients with recurrent squamous cell carcinoma of cervix uteri no longer amenable to control with surgery and/or radiotherapy were treated with a combination of ifosfamide, 5-fluorouracil, and Leucovorin every 4 weeks. The response rate was 53% (complete response, 33%; partial response, 20%). Response rates outside and inside irradiated area were 68 and 27%, respectively. The median progression-free interval was 7 months, and the median overall survival was 12 months. Adverse effects included primarily leukopenia, and dose reduction was necessary in 18 patients (60%). The present combination is active in the treatment of recurrent cervical cancer with a high response rate. The long-term survival is however still unsatisfactory.
Stornes
I
I
Department of Oncology, Aarhus University Hospital, Denmark.
Mejlholm
I
I
Jakobsen
A
A
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D002955:Leucovorin; D005472:Fluorouracil; D007069:Ifosfamide